Valuation: Exelixis, Inc.

Market Cap 13.12B 11.36B 10.62B 9.7B 18.29B 1,252B 18.57B 125B 48.86B 626B 49.27B 48.2B 2,085B P/E 2026 *
16.4x
P/E 2027 * 14.2x
Enterprise Value 12.38B 10.72B 10.02B 9.15B 17.25B 1,181B 17.52B 117B 46.09B 591B 46.48B 45.46B 1,967B EV / Sales 2026 *
4.85x
EV / Sales 2027 * 4x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-2.05%
1 week-3.81%
Current month-0.13%
1 month-6.27%
3 months+9.97%
6 months+23.22%
Current year+20.83%
1 week 51.76
Extreme 51.76
56.95
1 month 51.76
Extreme 51.76
56.95
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
5/27/26 Free

Director

8,367 0.0033%
2/26/26 Free

General Counsel

23,119 0.0086%
2/26/26 Free

Executive/Senior Manager

40,459 0.0151%
Change 5-day change 1-year change 3-year change Capi.($)
-2.05%-3.81%+40.40%+150.40% 13.12B
+4.21%+25.56%+77.96%+104.49% 70.85B
-0.99%+6.20%+34.94%+67.83% 55.41B
+2.78%+36.87%+23.00%+493.09% 29.43B
-0.30%+18.87%+57.08%+5.18% 24.12B
-0.93%+0.60%-16.89%-12.00% 23.31B
+0.55%+7.91%+44.14%-22.61% 18.37B
+7.26%+14.16%+221.03%+393.89% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
+0.78%+2.70%+437.94%+204.90% 12.48B
Average +1.07%+8.99%+95.07%+201.41% 28.02B
Weighted average by Cap. +1.67%+11.01%+72.03%+165.79%

Financials

2026 *2027 *
Net sales 2.55B 2.21B 2.06B 1.89B 3.56B 243B 3.61B 24.21B 9.5B 122B 9.58B 9.37B 405B 2.87B 2.49B 2.33B 2.13B 4.01B 274B 4.07B 27.28B 10.7B 137B 10.79B 10.56B 457B
Net income 814M 705M 659M 602M 1.14B 77.68B 1.15B 7.73B 3.03B 38.86B 3.06B 2.99B 129B 963M 834M 779M 712M 1.34B 91.87B 1.36B 9.14B 3.59B 45.96B 3.62B 3.54B 153B
Net Debt -744M -644M -602M -551M -1.04B -71B -1.05B -7.06B -2.77B -35.52B -2.8B -2.73B -118B -1.62B -1.4B -1.31B -1.2B -2.26B -155B -2.3B -15.4B -6.04B -77.42B -6.09B -5.96B -258B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-08-10 $52.96 -2.05% 3,349,673
26-08-07 $54.07 +3.58% 3,550,012
26-08-06 $52.20 -7.94% 5,410,948
26-08-05 $56.70 +1.25% 4,202,047
26-08-04 $56.00 +1.71% 2,729,948
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
52.96USD
Average target price
52.94USD
Spread / Average Target
-0.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock